Literature DB >> 10813499

The epidemiology of schistosomiasis in Egypt: Gharbia Governorate.

A M El-Hawey1, M M Amr, A H Abdel-Rahman, S A El-Ibiary, A M Agina, M A Abdel-Hafez, A A Waheeb, M H Hussein, G T Strickland.   

Abstract

Health questionnaires and parasitologic examinations of urine and stool were performed upon a stratified random sample of 14,344 individuals from 1,952 households in 34 rural communities in Gharbia Governorate of Egypt to investigate the prevalence of, risk factors for, and changing pattern of infection with Schistosoma sp. A subset, every fifth household, of 1,973 subjects had physical and ultrasound examinations to investigate prevalence of and risk factors for morbidity. Community prevalence of Schistosoma mansoni ranged from 17.9% to 79.5% and averaged 37.7%. The geometric mean egg count (GMEC) was 78.9 eggs/gram of feces. The prevalence and intensity of infection was 40-50% and 70-100 eggs/gram of feces in those > or =10 years of age. Schistosoma haematobium was detected in 5 of the 34 communities. The maximum infection rate was 2.8% and mean GMEC in the five communities was 2.1/10 ml of urine. The overall prevalence of S. haematobium in the governorate was 0.3%. Risk factors for infection with S. mansoni were male gender, an age >10 years, living in smaller communities, exposures to canal water, prior therapy for schistosomiasis, or blood in the stool (in children only). Morbidity detected by physical examination or ultrasonography did not correlate with S. mansoni infection in individuals with the exception of periportal fibrosis (PPF, odds ratio [OR] = 1.25). Periportal fibrosis was detected in more than half of the subjects by ultrasonography; 5.3% had grade II lesions and 1.0% had the most severe grade III changes. Risk factors for morbidity as manifested by ultrasonographically detected PPF were similar to those for infection. Periportal fibrosis had a negative relationship with abdominal pain (OR = 0.45) and hepatomegaly detected by physical examination and ultrasonography (ORs = 0.72 and 0.68), but it was associated with splenomegaly (ORs = 4.14 and 3.55). The prevalence of PPF, hepatomegaly, and splenomegaly increased with age. There was no relationship between community burden of schistosomiasis mansoni and any measurements of morbidity with the exception of splenomegaly detected by physical examination (r = 0.40). Schistosoma mansoni has almost completely replaced S. haematobium in Gharbia, which has a high prevalence and moderate intensity of S. mansoni infection. Periportal fibrosis was detected by ultrasonography in more than half of the subjects, and 1 in 16 had grade II and III lesions. The only relationship between PPF and other morbidity findings was its positive relationship with splenomegaly and negative association with hepatomegaly. Hepatic morbidity is common in communities in Gharbia but the role of schistosomiasis mansoni in this is uncertain.

Entities:  

Mesh:

Year:  2000        PMID: 10813499     DOI: 10.4269/ajtmh.2000.62.42

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt.

Authors:  Amr S Soliman; Chu-Wei Hung; Alexander Tsodikov; Ibrahim A Seifeldin; Mohamed Ramadan; Dina Al-Gamal; Emily L Schiefelbein; Priyanka Thummalapally; Subhojit Dey; Kadry Ismail
Journal:  Hepatol Int       Date:  2010-08-19       Impact factor: 6.047

2.  Meta-analysis of the diagnostic efficiency of the questionnaires screening for schistosomiasis.

Authors:  Fen Yang; Xiao-Dong Tan; Bei Liu; Chongming Yang; Zi-Ling Ni; Xu-Dong Gao; Ying Wang
Journal:  Parasitol Res       Date:  2015-06-28       Impact factor: 2.289

3.  Predicting the habitat suitability of Schistosoma intermediate host Bulinus truncatus, its predatory aquatic insect Odonata nymph, and the associated aquatic plant Ceratophyllum demersum using MaxEnt.

Authors:  Marwa M Mahmoud; Aly A Younes; Hanaa A El-Sherif; Fathia A Gawish; Mohamed R Habib; Mohamed Kamel
Journal:  Parasitol Res       Date:  2022-01-04       Impact factor: 2.289

4.  Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.

Authors:  Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

5.  Incidence analyses of bladder cancer in the Nile delta region of Egypt.

Authors:  Stacey A Fedewa; Amr S Soliman; Kadry Ismail; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Hoda G Omar; Jerome Nriagu; Mark L Wilson
Journal:  Cancer Epidemiol       Date:  2009-09-16       Impact factor: 2.984

6.  Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.

Authors:  Olfat Ali Hammam; Ahmed A Aziz; Mamdouh S Roshdy; Ahmed M Abdel Hadi
Journal:  Medscape J Med       Date:  2008-03-11

7.  Persistent Colonic Schistosomiasis among Symptomatic Rural Inhabitants in the Egyptian Nile Delta.

Authors:  Mohamed Hussien Ahmed; Mohamed H Emara; Amr Asem Elfert; Aymen M El-Saka; Asem Ahmed Elfert; Sherief Abd-Elsalam; Mohamed Yousef
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

8.  Levels of certain tumor markers as differential factors between bilharzial and non-biharzial bladder cancer among Egyptian patients.

Authors:  Nadia S Metwally; Sanaa A Ali; Azza M Mohamed; Hussein M Khaled; Samia A Ahmed
Journal:  Cancer Cell Int       Date:  2011-04-07       Impact factor: 5.722

Review 9.  Epidemiology of Schistosomiasis in Egypt: Travel through Time: Review.

Authors:  Rashida M R Barakat
Journal:  J Adv Res       Date:  2012-09-04       Impact factor: 10.479

10.  Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Haider S Kadhim; Fatimah Abubakar
Journal:  J Exp Clin Cancer Res       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.